Administration of gedunin suppressed the development of BPH carcinomas by inhibiting the PI3K/Akt and NF-κB pathways by inactivating Akt and the inhibitory kappa B kinase (IKK), respectively. This evidence concerns the gene NFKB1 and benign prostatic hyperplasia.